Afficher la notice abrégée

Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies

dc.rights.licenseopenen_US
dc.contributor.authorSACKS-DAVIS, Rachel
dc.contributor.authorVAN SANTEN, Daniela K
dc.contributor.authorBOYD, Anders
dc.contributor.authorYOUNG, Jim
dc.contributor.authorSTEWART, Ashleigh
dc.contributor.authorDOYLE, Joseph S
dc.contributor.authorRAUCH, Andri
dc.contributor.authorMUGGLIN, Catrina
dc.contributor.authorKLEIN, Marina
dc.contributor.authorVAN DER VALK, Marc
dc.contributor.authorSMIT, Colette
dc.contributor.authorJARRIN, Inmaculada
dc.contributor.authorBERENGUER, Juan
dc.contributor.authorLACOMBE, Karine
dc.contributor.authorREQUENA, Maria-Bernarda
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLELEUX, Olivier
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorSALMON, Dominique
dc.contributor.authorMATTHEWS, Gail V
dc.contributor.authorGUY, Rebecca
dc.contributor.authorMARTIN, Natasha K
dc.contributor.authorSPELMAN, Tim
dc.contributor.authorPRINS, Maria
dc.contributor.authorSTOOVE, Mark
dc.contributor.authorHELLARD, Margaret
dc.date.accessioned2024-02-20T13:35:11Z
dc.date.available2024-02-20T13:35:11Z
dc.date.issued2024-01-12
dc.identifier.issn2352-3018en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188263
dc.description.abstractEnBACKGROUND: Reinfection after successful treatment with direct-acting antivirals is hypothesised to undermine efforts to eliminate hepatitis C virus (HCV) infection among people with HIV. We aimed to assess changes in incidence of HCV reinfection among people with HIV following the introduction of direct-acting antivirals, and the proportion of all incident cases attributable to reinfection. METHODS: We pooled individual-level data on HCV reinfection in people with HIV after spontaneous or treatment-induced clearance of HCV from six cohorts contributing data to the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) in Australia, Canada, France, the Netherlands, Spain, and Switzerland between Jan 1, 2010, and Dec 31, 2019. Participants were eligible if they had evidence of an HCV infection (HCV antibody or RNA positive test) followed by spontaneous clearance or treatment-induced clearance, with at least one HCV RNA test after clearance enabling measurement of reinfection. We assessed differences in first reinfection incidence between direct-acting antiviral access periods (pre-direct-acting antiviral, limited access [access restricted to people with moderate or severe liver disease and other priority groups], and broad access [access for all patients with chronic HCV]) using Poisson regression. We estimated changes in combined HCV incidence (primary and reinfection) and the relative contribution of infection type by calendar year. FINDINGS: Overall, 6144 people with HIV who were at risk of HCV reinfection (median age 49 years [IQR 42-54]; 4989 [81%] male; 2836 [46%] men who have sex with men; 2360 [38%] people who inject drugs) were followed up for 17 303 person-years and were included in this analysis. The incidence of first HCV reinfection was stable during the period before the introduction of direct-acting antivirals (pre-introduction period; 4·1 cases per 100 person-years, 95% CI 2·8-6·0). Compared with the pre-introduction period, the average incidence of reinfection was 4% lower during the period of limited access (incidence rate ratio [IRR] 0·96, 95% CI 0·78-1·19), and 28% lower during the period of broad access (0·72, 0·60-0·86). Between 2015 and 2019, the proportion of incident HCV infections due to reinfection increased, but combined incidence declined by 34%, from 1·02 cases per 100 person-years (95% CI 0·96-1·07) in 2015 to 0·67 cases per 100 person-years (95% CI 0·59-0·75) in 2019. INTERPRETATION: HCV reinfection incidence and combined incidence declined in people with HIV following direct-acting antiviral introduction, suggesting reinfection has not affected elimination efforts among people with HIV in InCHEHC countries. The proportion of incident HCV cases due to reinfection was highest during periods of broad access to direct-acting antivirals, highlighting the importance of reducing ongoing risks and continuing testing in people at risk. FUNDING: Australian National Health and Medical Research Council.
dc.language.isoENen_US
dc.title.enChanges in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies
dc.title.alternativeLancet HIVen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/s2352-3018(23)00267-9en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38224708en_US
bordeaux.journalLancet HIVen_US
bordeaux.pagee106-e116en_US
bordeaux.volume11en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIAen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04468540
hal.version1
hal.date.transferred2024-02-20T13:35:14Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Lancet%20HIV&rft.date=2024-01-12&rft.volume=11&rft.issue=2&rft.spage=e106-e116&rft.epage=e106-e116&rft.eissn=2352-3018&rft.issn=2352-3018&rft.au=SACKS-DAVIS,%20Rachel&VAN%20SANTEN,%20Daniela%20K&BOYD,%20Anders&YOUNG,%20Jim&STEWART,%20Ashleigh&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée